Drug Name,MOA,Experiment,Method,Parameter,Mean,Unit
H1H15211P,Signal Transduction Modulators;Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus),"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,4.74E-11,M
90-F1,Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus),"Spike Glycoprotein (MERS-CoV) affinity, IN VITRO",Surface plasmon resonance assay,Kd,7.20E-11,M
MERS-4V2,Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus),"Spike Glycoprotein (MERS-CoV) affinity, IN VITRO",ELISA assay,Kd,7.32E-10,M
Chloroquine,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,8.00E-10,M
Nafamostat mesilate,Tryptase Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Vero cells (TMPRSS2-expressing) transfected with MERS,IC-50,1.00E-09,M
Silvestrol,Eukaryotic Initiation Factor 4A (eIF4A) Inhibitors;Apoptosis Inducers,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Plaque assay,IC-50,1.30E-09,M
BanLec,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,3.99E-09,M
Remdesivir,Nucleobindin-1 (NUCB1) Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-50,1.00E-08,M
SR9EK1,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-90,1.25E-08,M
Lycorine,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Dye assay,IC-50,1.57E-08,M
Noscapine,Tubulin Polymerization Inhibitors;Apoptosis Inducers;Antimitotic Drugs,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-90,2.20E-08,g/l
"6',6'-Difluoroaristeromycin",S-Adenosyl-L-Homocysteine Hydrolase Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Plaque assay,MIC,1.00E-07,M
Azithromycin,Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,1.00E-07,M
IIS,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,1.00E-07,M
Niclosamide,Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.00E-07,M
Promazine,Signal Transduction Modulators;Dopamine Receptor Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,MIC,1.00E-07,M
SR9EK2,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-90,1.08E-07,M
IIQ,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,1.10E-07,M
TG-0205221,3C-Like Protease (SARS-CoV) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Plaque assay,IC-50,1.40E-07,M
Emetine,Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.50E-07,M
GC-376,3C-Like Protease (Norovirus) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,1.50E-07,M
Mycophenolic acid sodium salt,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.70E-07,M
JMF-1521,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.80E-07,M
Cycloheximide,Signal Transduction Modulators;Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Ferroptosis Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.90E-07,M
GC-373,3C-Like Protease (Norovirus) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,2.00E-07,M
Mycophenolate mofetil,Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,2.30E-07,M
N-3,3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",MCA-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-lys(Dnp)-lys-NH2 as substrate,Ki,2.30E-07,M
P-21S8,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,2.60E-07,M
Rupintrivir,HRV 3C Protease Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,3.00E-07,M
Chloroquine phosphate,Apoptosis Inducers,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,3.06E-07,M
GRL-0667,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,3.20E-07,M
P-21S10,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein,IC-50,3.30E-07,M
Sinefungin,Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",,IC-50,3.83E-07,M
KIN-269,Interferon Regulatory Factor 3 (IRF-3) Activators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.90E-07,M
Gemcitabine hydrochloride,Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,4.40E-07,M
GRL-0617,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,5.60E-07,M
HR2P,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.00E-07,M
M-34,Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus),"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",,IC-50,6.00E-07,g/l
Betulonic acid,Lysosomal alpha-Glucosidase (GAA) Inhibitors;E3 Ubiquitin-Protein Ligase Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.30E-07,M
HR2P-M2,Viral Fusion Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,6.40E-07,M
KIN-1160,Interferon Regulatory Factor 3 (IRF-3) Activators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,6.91E-07,M
Tanshinone I,Signal Transduction Modulators;AP-1 Transcription Factor Complex Inhibitors;Aryl Hydrocarbon Receptor (AhR) Ligands,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Ubiquitin-7-amino-4-methylcoumarin as substrate,IC-50,7.00E-07,M
[N-MeIle4]-cyclosporin,Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,8.00E-07,M
Alisporivir,P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,8.00E-07,M
Ciclosporin,Cyclophilin D Inhibitors;Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;INS Expression Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,9.00E-07,M
Geldanamycin,Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",,IC-50,9.10E-07,M
NSC-158362,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-50,1.00E-06,M
(-)-Savinin,Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.13E-06,M
Dihydrotan,"Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Immune Checkpoint Inhibitors;Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors","Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Ubiquitin-7-amino-4-methylcoumarin as substrate,IC-50,1.20E-06,M
SR9EK3,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-90,1.23E-06,M
Monensin A sodium salt,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,1.25E-06,M
Ferruginol,3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,1.39E-06,M
Ferroquine,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",,IC-50,1.40E-06,M
Apigenin,NMDA Receptor Antagonists;Cytochrome P450 CYP1A2 Inhibitors;Ornithine Decarboxylase Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Signal Transduction Modulators;MAO-A Inhibitors;Xanthine Oxidase Inhibitors;Apoptosis Inducers;Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Inhibitors;VEGF Expression Inhibitors;Angiogenesis Inhibitors;GABA(A) Receptor Antagonists;Nitric Oxide (NO) Production Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,1.70E-06,M
Ganciclovir,DNA Polymerase Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Dye assay (MTS),IC-50,1.70E-06,g/l
"3,4-Dihydroxyamphetamine",,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Dye assay (MTS),IC-50,2.00E-06,g/l
Phenazopyridine hydrochloride,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,2.02E-06,M
Chlorpyrifos,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,2.27E-06,M
Chlorpromazine,Signal Transduction Modulators;Dopamine D2 Receptor (DRD2) Antagonists;Kinesin-Like Spindle Protein KIF11 (KSP; Eg5) Inhibitors;Antimitotic Drugs,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Gene reporter assay,IC-50,2.50E-06,M
Hirsutenone,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;LDL Antioxidants;Signal Transduction Modulators;Antiinflammatory Drugs;Free Radical Scavengers;Nitric Oxide (NO) Production Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Ubiquitin-7-amino-4-methylcoumarin as substrate,IC-50,3.00E-06,M
Fluphenazine hydrochloride,Signal Transduction Modulators;Nicotinic alpha7 Receptor Ligands;Dopamine D2 Receptor (DRD2) Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.23E-06,M
K-22,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,3.30E-06,M
Triflupromazine hydrochloride,Signal Transduction Modulators;Nicotinic alpha7 Receptor Ligands,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.32E-06,M
Astemizole,Histamine H1 Receptor Antagonists;Signal Transduction Modulators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.48E-06,M
Papyriflavonol A,Signal Transduction Modulators;Phospholipase A2 (PLA2) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Fluorescent assay,IC-50,3.70E-06,M
Berberine iodide,DNA-Intercalating Drugs;Insulin Secretagogues;Signal Transduction Modulators;AMP-Activated Protein Kinase (AMPK) Activators;Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Potassium Channel Blockers;Acetylcholinesterase (AChE) Inhibitors;LDL-Receptor Up-Regulators;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,3.80E-06,M
Loperamide hydrochloride,Signal Transduction Modulators;mu-Opioid Receptor Agonists;Atrial Natriuretic Peptide B (NPR2; Guanylate Cyclase B) Receptor Antagonists,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Gene reporter assay,IC-50,4.00E-06,M
Retro-94,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",,IC-50,4.10E-06,M
Psoralidin,Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,4.20E-06,M
Quinacrine hydrochloride,Secretory Phospholipase A2 (sPLA2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Cytokine Production Inhibitors;TP53 Expression Enhancers,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",,IC-50,4.20E-06,M
KIN-101,Interferon Regulatory Factor 3 (IRF-3) Activators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,4.50E-06,M
Saquinavir,HIV Protease Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,MIC,4.66E-06,M
24F2-2,Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus),"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Luciferine/luciferase assay,IC-50,4.89E-06,g/l
Imatinib mesylate,Tyrosine-Protein Kinase ABL1 Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;KIT (C-KIT) Inhibitors;CSF1R (c-FMS) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",RNA assay,MIC,5.00E-06,M
S377-588-Fc,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, EX VIVO",ELISA assay,MED,5.00E-06,g
Tomentin E,Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,5.00E-06,M
Dasatinib,"Tyrosine-Protein Kinase Lck (LCK) Inhibitors;Tyrosine-Protein Kinase ABL1 Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Signal Transduction Modulators;Lyn Kinase Inhibitors;PDGFRbeta Inhibitors;Anti-LRPPRC (Leucine-Rich PPR Motif-Containing Protein, Mitochondrial);KIT (C-KIT) Inhibitors;Ephrin type-A receptor 2 (EPHA2) Receptor Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;Discoidin Domain-Containing Receptor 1 (DDR1) Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors;Tyrosine-Protein Kinase CSK Inhibitors;Angiogenesis Inhibitors;Tyrosine Kinase Inhibitors;Yes Kinase Inhibitors;Fyn Kinase Inhibitors","Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,5.47E-06,M
Lopinavir,HIV Protease Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Viral replication assay,IC-50,5.60E-06,M
Curcumin,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;CCND1 Expression Inhibitors;Glucose-6-Phosphatase Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;HIV Integrase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Antiinflammatory Drugs;Histone N-Acetyltransferase (HAT) Inhibitors;Microtubule-Associated Protein Tau (PHF-tau; MAPT) Aggregation Inhibitors;AP-1 Transcription Factor Complex Inhibitors;DNA Methyltransferase 1 (DNMT1) Inhibitors;Apoptosis Inducers;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Antioxidants;Angiogenesis Inhibitors;EGFR Expression Inhibitors;Cell Division Protein FtsZ (Bacterial) Inhibitors;Free Radical Scavengers;Lipoxygenase Inhibitors;Wnt Signaling Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,5.70E-06,M
RH-01,3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",,IC-50,5.72E-06,M
Tiotixene,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,5.74E-06,M
SG-85,3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C Protease (Enterovirus 71) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",,IC-50,6.06E-06,M
Amodiaquine hydrochloride,,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,6.21E-06,M
Tacrolimus,Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",RNA assay,IC-50,6.60E-06,M
Quercetin,Catechol-O-Methyl Transferase (COMT) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Signal Transduction Modulators;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Xanthine Oxidase Inhibitors;EGFR (HER1; erbB1) Inhibitors;Cytokine Production Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Aldose Reductase Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Free Radical Scavengers;Epigenetic Modifier Modulators;Wnt Signaling Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Uncompetitive inhibition mode,Ki,7.00E-06,M
Mucroporin-M1,Cell Membrane Disrupting Agents,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Plaque assay,IC-50,7.12E-06,M
Isobavachalcone,Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,IC-50,7.30E-06,M
Tamoxifen citrate,Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,7.46E-06,M
Promethazine hydrochloride,Histamine H1 Receptor Antagonists;Signal Transduction Modulators,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,7.48E-06,M
Bavachinin,Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;beta-Amyloid (Abeta) Aggregation Inhibitors;MAO-B Inhibitors;Signal Transduction Modulators;PPAR Agonists;Apoptosis Inducers;Antioxidants;beta-Secretase 1 (BACE1) Inhibitors;Antiamyloidogenic Agents,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",,IC-50,7.90E-06,M
Broussochalcone A,Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Uncompetitive inhibition mode,Ki,8.00E-06,M
Nelfinavir mesilate,HIV-1 Protease Inhibitors;Proteasome Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,8.19E-06,M
Hydroxychloroquine sulfate,Palmitoyl-Protein Thioesterase 1 (PPT1) Inhibitors;Autophagy Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,8.28E-06,M
Clomipramine hydrochloride,Signal Transduction Modulators;Serotonin Transporter (SERT) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",,IC-50,8.79E-06,M
HP-083,,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,IC-50,8.80E-06,M
SSYA-10-001,,"Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO",Viral replication assay,IC-50,8.95E-06,M
Cryptotanshinone,Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;Signal Transduction Modulators;Antiinflammatory Drugs;Antioxidants;Aldose Reductase Inhibitors;Angiogenesis Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,Ki,9.00E-06,M
Tioguanine,Purine Antagonists,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Competitive inhibition mode,Ki,9.10E-06,M
Methyltanshinonate,,"Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO",Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate,Ki,9.70E-06,M
Efavirenz,Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors,"Coronavirus acute respiratory syndrome remission/reduction, IN VITRO",Cytopathicity assay,MIC,9.90E-06,M
Ribavirin,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors,"Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO",Cytopathicity assay,IC-50,9.99E-06,M